Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.38
(
-1.01%
)
Bitcoin
70,110.00
(
0.30%
)
News Focus
News Focus
Post# of 57560
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: atheroprevent post# 32646

Monday, 03/15/2010 3:46:26 PM

Monday, March 15, 2010 3:46:26 PM

Post# of 57560
Good point on the combination product called Valturna (#msg-41609619), which might suffer a modest setback from the failed Diovan study. However, the main reason for the slow uptake of Valturna has been that the medical community has not (yet) been sold on the benefits of the Tekturna component. Regards, Dew


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now